Phase II trial of dose dense neo-adjuvant gemcitabine, epirubicin, ABI-007 [paclitaxel] (GEA) in locally advanced or inflammatory breast cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2013
At a glance
- Drugs Epirubicin; Gemcitabine; Paclitaxel; Pegfilgrastim
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 02 May 2011 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.